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The preparation of aminoalkyl phenyl selenides and 
pharmaceutically acceptable salts thereof is disclosed 
which are useful for the treatment of hypertension and 
related vascular diseases and the treatment of nervous 
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AMINOALKYLPHENYLSELENIDESFORTHE 
TREATMENT OF HYPERTENSION AND 
NERVOUS SYSTEM DYSFUNCTIONS 
resultant selenoxide product, spontaneous consumption 
of additional equivalents of ascorbic acid accompanies 
the reduction of this selenoxide product back to the 
original enzyme substrate form (e.g., back to the sele-
BACKGROUND OF THE INVENTION 
This is a continuation of co-pending application Ser. 
No. 643,556 filed on Aug. 23, 1984, now U.S. Pat. No. 
4,579,870 issued April 1986. 
5 nide). Thus, it is suggested that the infusion of a chosen 
derivative of this invention as the enzyme substrate 
results in an oxygenation/reduction cycle initiated and 
sustained by the target enzyme dopamine-beta-
hydroxylase, which operates at the expense of intracel-
1. Field of the Invention 
This invention relates to the synthesis of aminoalkyl 
phenyl selenides useful for the treatment of hyperten-
sion and nervous system dysfunctions. 
10 lular ascorbic acid stores. This process can be used 
pharmaceutically to inhibit (reversibly) the function of 
adrenergic neurons in several locations in the body, 
including the central nervous system, the peripheral 
2. Description of the Prior Art 
Phenolic aryl-seleno and aryl-thio compounds and 15 
other selenide and sulfide derivatives have been dis-
closed for use as photographic couplers. Lau, Phillip T. 
S., Arylthio (or seleno, or sulfonyl) Methyl-Substituted 
Phenolic Compounds As Photographic Couplers, 
Chem. Abstracts 80:82391. Neither the structures, nor 20 
the use disclosed by Lau are related to the compositions 
of the present invention. 
May et al., U.S. Pat. No. 4,415,591 of Nov. 15, 1983, 
which patent is assigned in common herewith, the sub-
ject matter of which is incorporated herein by refer- 25 
ence, discloses a method for treating hypertension in-
volving the administration of aminoalkyl phenyl sulfide 
derivatives; there is also disclosed a method for evaluat-
ing the hypotensive potential of these compounds 
through the rate of enzymatic oxygenation by dopa- 30 
mine-beta-hydroxylase in the presence of an electron 
donor such as hexacyanoferrate (II) or ascorbic acid; 
and pharmaceutical compositions are also disclosed 
which comprise aminoalkyl phenyl sulfide or a salt 
thereof in amount effective for treatment of hyperten- 35 
sion, a monoamine oxidase inhibitor and a nontoxic 
excipient. 
As compared with the .May et al. patent, this inven-
tion involves specifically different pharmaceutical com-
pounds namely, aminoalkyl phenyl selenides and the 40 
salts thereof, which have been found not only to cause 
substantial systemic blood pressure reduction, but may 
also provide potent clinical benefits with respect to 
nervous system dysfunctions and, in particular due to 
the unusual electrochemical properties of the selenoxide 45 
compound produced by the enzymatic oxygenation of 
the selenide, to enable reversible inhibition of the func-
tion of adrenergic neurons. This reversible inhibition is 
due to depletion of intracellular ascorbate, as more fully 
described below in the Detailed Description of the 50 
Invention and Preferred Embodiments. 
While organosulfur chemistry is paralleled in a num-
ber of aspects by organoselenium chemistry, the facility 
of oxidation and reduction reactions can differ greatly. 
Riech, H. J. (1978), Oxidation in Organic Chemistry 55 
(Trahanovsky, W. ed.), Part C. pp 1-129, Academic 
Press, London and New York. For example, it has been 
reported that the monooxygenase activity of Aspergillus 
niger does not produce selenoxides from selenide sub-
strates, despite the ready sulfoxidation of sulfides under 60 
the same conditions. The invention herein is believed to 
be the first example of selenoxidation by a specific mo-
nooxygenase, namely, dopamine-beta-hydroxylase. 
The compounds of this invention, acting as substrates 
for the enzyme dopamine-beta-hydroxylase, consume 65 
two equivalents of ascorbic acid in the normal oxygena-
tion process of dopamine-beta-hydroxylase. However, 
due to the unusual electrochemical properties of the 
nervous system, and the adrenal glands. This result is 
highly unexpected and appears to result from and be 
limited to the phenyl selenides of this invention. 
The prior art does not teach the aminoalkyl phenyl 
selenides or pharmaceutically acceptable salts thereof, 
nor the unexpected depletion of intracellular ascorbic 
acid which is characteristic of this invention. 
BRIEF SUMMARY OF THE INVENTION 
Accordingly, it is an object of this invention to pro-
vide a new class of compounds suitable for the treat-
ment of hypertension and related vascular diseases, and 
for the treatment of nervous system dysfunctions by the 
direct intrinsic activity of these compounds and by the 
metabolic products of these compounds after enzymatic 
activation. 
Another object of this invention is to provide new 
compounds which possess a phenyl selenide group lo-
cated within the drug molecule at a position which 
makes these molecules possess activity at neurochemi-
cal receptors and which makes them effective substrates 
for a specific oxygenase, dopamine-beta-hydroxylase, 
which can convert them into selenoxide species capable 
of gently modifying both neuronal function and cardio-
vascular tone. The selenide compounds as well as their 
enzyme products can interact with normal uptake and 
catabolic pathways to potentiate their effects and to aid 
in the normal elimination of these compounds from the 
body. 
An important object of this invention is to provide a 
new class of compounds displaying a new approach to 
the treatment of the pathologies of the human cardio-
vascular and nervous system. The intrinsic activities of 
the phenyl selenides of this invention are potentiated by 
their enzymatic conversion from relatively inactive 
pro-drug precursors into highly active enzyme prod-
ucts. 
These objects may be attained by treatment of an 
effective amount of aminoalkyl phenyl selenide deriva-
tive having the formula: 
*
R4 Rs R
6 
RJ Se-(CHx)n-N~ 
R1 
R1 R1 
wherein: 
R1-R1=H, OH, C1-C4-alkoxy, C1-C4-alkyl, F, Cl, 
Br, I; 
(CHx)n=any straight or branched, saturated or un-
saturated alkyl chain of 1 to 10 carbons (x-0, 1,2); 
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and pharmaceutically acceptable addition salts 
thereof. 
BRIEF DESCRIPTION OF THE DRAWING 
The FIGURE of the drawing is a graphic depiction 5 
of the cyclic path of ascorbate oxidation by the aminoal-
kyl phenyl selenides of the present invention. 
was dissolved into 100 ml of tetrahydrofuran (THF) 
with steam heating. To the intensely dark red THF 
solution was added 9.84 ml (9S mmol, 1.2 eq.) of SO% 
hypophosphorous acid and the reaction was refluxed 
under argon for 6 hours, cooled, and diluted with 200 
ml of EtiO and washed with 200 ml of 0.127M NaOAc 
buffer pH S.O to remove the phosphoric acid by-pro-
duct. Both the Et20 and the buffer were deoxygenated 
by bubbling argon through fritted glass for over 1 hour DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED 
EMBODIMENTS 10 in order to prevent reoxidation of phenylselenol to diphenyl diselenide. The washed organic phase was 
The compounds used in this invention are in general then concentrated to yield a yellow oil (diselenide con-
parallel to the compounds disclosed in the May et al. taminant) with residual salt-containing water pockets. 
U.S. Pat. No. 4,41S,S91 with the important distinction The crude product was pumped down to remove resid-
that the phenyl sulfide group of that patent is replaced 15 ual solvent prior to distillation, which yielded the de-
by the phenyl selenide group of this invention to yield sired phenylselenol (12.6 g, S 1 % yield). pNMR 
the capability for depletion of intracellular ascorbic (CDCh) (s, lH) 1.S4 d (m, SH) 7.3S d. Yields as high as 
acid. Thus, the phenyl ring can be substituted or unsub- 70% have been obtained for this reaction. 
stituted, and the alkyl moiety between the selenium The phenylselenol obtained was refluxed under argon 
atom and the amino group may be any linear or 20 overnight with 7.S ml (88.4S ml, 1.1 eq.) of 2-methyl-2-
branched, saturated or unsaturated chain of 1 to 10 oxazoline and 3 ml of benzene. Upon cooling, the entire 
carbons. Suitable substituents R1-R1 include H, OH, reaction solidified to a dense pale yellow solid which 
C1-C4-alkyl groups, such as methyl, ethyl, n-propyl, was recrystallized from benzene to yield 18.076 g (74.63 
isopropyl, n-butyl, isobutyl, secbutyl, and t-butyl; mmol, 92.8% yield) of N-acetyl-phenyl-aminoethyl 
C1-C4-alkoxy groups such as methoxy, ethoxy, n- 25 selenide as shiny white plates. pNMR (CDCl3) (s, 3H) 
propoxy, isopropoxy, n-butoxy, isobutoxy, secbutoxy, 1.90 d, (m, 2H) 3.08 d, (m, 2H) 3.S7 d J =6 Hz, (broad s, 
t-butoxy, hydroxy, and halogen, such as fluorine, chlo- lH) 6.11 d, (m, 5h) 7.48 d. mass spec (m/e 243 molecular 
rine, bromine and iodine. Suitable groups for the alkyl ion). 
moiety between the selenium atom and the amino group The acetamide was hydrolyzed by refluxing over-
include methylene, ethylene, 1,3-propylene, 1,4-buty- 30 night in 100 ml of 6M HCl. The solution was then 
lene, 1,6-hexylene, octamethylene, decamethylene, 2- cooled in an ice bath and basified to pH 13 by the slow 
methyl-1,3- propylene, 3-methyl-1,S-pentylene, 3-ethyl- addition of solid NaOH, extracted with four 2S ml por-
1-1,S-pentylene, 2-ethyl-1,6-pentylene, 2-ethyl-1,6- tions of CHCh, and the combined chloroform extracts 
hexylene, 2-ethyl-1,8-octylene, S-methyl-1,9,nonylene, were dried over anhydrous K1C03, filtered, and the 
and the like. 35 solvent removed in vacuo to yield lS.680 g of the free 
Suitable compounds useful in this invention include amine (plus residual CHCIJ) as a clear yellow liquid. 
phenyl-2-aminoethyl selenide, 2-(methylamino )ethyl The hydrochloride salt was obtained by the addition of 
phenyl selenide, 2-(dimethylamino)ethyl phenyl sele- 6.5mlof12M HCl (1.0S eq) to 60 ml of a EtOH/EtiO 
nide, 2-(ethylamino)ethyl phenyl selenide, 2-(n- (2:1) solution of the free amine. Recrystalization from 
. propylamino)ethyl phenyl selenide, 2-(n- 40 EtOH/Et20 (2:1) yielded the final product; mp 
butylamino)ethyl phenyl selenide, 2-aminoethyl 4- 149.2°-lS0.7° C., loss of crystal structure at 131° C.; 
.hydroxyphenyl selenide, 2-aminoethyl 3,4-dihydrox- pNMR (020) (s, 4H) 3.21 d, (m, SH) 7.S8 d; mass spec 
yphenyl selenide, 2-aminoethyl 3,S-dihydroxyphenyl (m/e 201 molecular ion); elemental analysis for 
selenide, 2-aminoethyl 4-methyl phenyl selenide, 2- CsH12CINSe THEORY C 40.61, H S.12, N S.92 
aminoethyl 2,4-dimethyl phenyl selenide, 2-amino-ethyl 45 FOUND C 40. 73, H S.11, N S.90. 
4-ethylphenyl selenide, 2-aminoethyl 4-propylphenyl Other aminoalkyl phenyl selenides of the present 
selenide, 2-aminoethyl 4-butylphenyl selenide, 2-amino- invention can be synthesized by generally following the 
ethyl 4-methoxyphenyl selenide, 2-aminoethyl 4-ethoxy above procedure. For compounds in which R6or R1 are 
phenyl selenide, 2-aminoethyl 4-propoxyphenyl sele- those other than H or acetoxy, the preparation of such 
nide, 2-amino-ethyl 4-butoxyphenyl selenide, 2-amino- 50 compounds involves the synthesis of the appropriately 
ethyl 3,4-dimethoxy phenyl selenide, 2-aminoethyl substituted halogenated side chain by standard methods 
3,4,S-trimethoxyphenyl selenide, 3-aminopropyl phenyl and subsequent nucleophilic attack by the chosen sele-
selenide, 4-aminobutyl phenyl selenide, 6-aminohexyl nide precursor, with appropriate blocking procedures 
phenyl selenide, 8-aminooctyl phenyl selenide, 10- familiar to those skilled in the art. 
aminodecyl phenyl selenide, 6-amino-2-ethylhexyl 55 When compounds of this invention are used as anti-
phenyl selenide, 3-amino-2-methylpropyl 3,4-dihydrox- hypertensive compounds, they may be administered 
yphenyl selenide, 4-amino-3-methylbutyl 3,4-dimethox- orally, parenterally or rectally and may be formulated 
yphenyl selenide, 4-methylamino-3-methylbutyl 3,4- in compositions and dosage forms for such administra-
dimethoxyphenyl selenide, and the like. tion. In these compositions and dosage forms the com-
The compounds used in this invention may also be 60 pounds are admixed with conventional nontoxic phar-
used in the form of their acid addition salts with non- maceutical excipients. Solid dosage forms for oral ad-
toxic pharmaceutically acceptable acids. Such salts ministration include capsules, tablets, pills, powders, 
include the hydrochloride, sulfate, hydrobromide, ci- and granules. In such solid dosage forms, the active 
trate, acetate, gluconate, and the like. compound is admixed with at least one inert diluent 
A preferred compound is phenyl-2-aminoethyl sele- 65 such as sucrose, lactose, or starch. Such dosage forms 
nide and salts thereof. Phenyl-2-aminoethyl selenide can also comprise, as is normal practice, additional 
(PAESe) was synthesized by employing the following substances other than inert diluents, e.g., lubricating 
procedure. Diphenyl diselenide, 24.707 g (79.16 mmol) agents such as magnesium stearate. In the case of cap-
5 
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sules, tablets, and pills, the dosage forms may also com- the co-administration of such "nonbranched" aminoal-
prise buffering agents. Tablets and pills can also be kyl phenyl selenides in combination with a monoamine 
prepared with an enteric coating. oxidase inhibitor. The combination of aminoalkyl 
Liquid dosage forms for oral administration include phenyl selenide derivatives and monoamine oxidase 
pharmaceutically acceptable emulsions, solutions, sus- 5 inhibitors such as clorgyline, deprenyl, nardil (phene-
pensions, syrups, and elixirs containing inert diluents thylhydrazine sulfate) or others currently in clinical use 
commonly used in the art, such as purified water and may protect the selenide or selenoxide product and 
alcohols. Besides inert diluents, such compositions can therefore allow a longer active period in the body, 
also include adjuvants, such as wetting agents, emulsify- resulting in an increased anti-hypertensive effect. 
ing and suspending agents, and sweetening, flavoring, 10 Although the exact mechanism by which the com-
and perfuming agents. Preparations according to this pounds used in the process of this invention exert their 
invention for parenteral administration include sterile physiological effect is uncertain, and applicants do not 
aqueous or nonaqueous solutions, suspension or emul- wish to be bound by any theoretical consideration, it is 
sions. Examples of nonaqueous solvents or vehicles are possible that the unique biochemical action, i.e. reduc-
propylene glycol, polyethylene glycol, vegetable oils 15 tion/oxidation properties of these compounds, may play 
such as olive oil and injectable organic esters such as a part in their activity alone or in combination with 
ethyl oleate. their action as false neurotransmitters as described in 
Compositions for rectal administration are supposito- the May et al. U.S. Pat. No. 4,415,591. Other mecha-
ries which may contain in addition to the active sub- nisms related to neuronal uptake and regulation of enzy-
stance, excipients such as cocoa butter or a suppository 20 matic activities may also be involved in the activities of 
wax. the compounds. 
The dosage of active ingredient in the compositions The effectiveness of the compounds used in the pro-
of this invention may be varied; however, it is necessary cess of this invention as anti-hypertensive agents can be 
that the amount of the active ingredient be such that a evaluated by an enzymatic oxygenation process as dis-
suitable dosage form is obtained. The selected dosage 25 closed in the aforesaid May et al. U.S. Pat. No. 
depends upon the desired therapeutic effect, on the 4,415,591, the subject matter of which is incorporated 
route of administration, and on the duration of the treat- herein by reference. Using the standard substrate 2-
ment. Generally, dosage levels of between 0.5 to 100 phenylethylamine, the carbon analog 3-phenylpropyla-
mg/kg of body weight daily are administered to mam- mine and the substrate phenyl-2-aminoethyl selenide of 
mals to obtain effective relief of hypertension. A pre- 30 this invention with ascorbic acid as the electron donor, 
ferred dosage level isl.Oto 50.0 mg/kg of body weight. the values of kcat. and kcatlKm using 300 micrograms 
The reduction of blood pressure varies with dosage per milliliter of catalase were 48s- I and 
levels. 2.9X I03M-15-I, respectively. 
The hydrochloride salt of phenyl-2-aminoethyl sele- As noted above, the enzymatic oxygenation products 
nide was administered in a commonly-used model of 35 of the compounds of this invention possess unusual 
human hypertension, the spontaneously hypertensive electro-chemical properties such that a unique aspect of 
rat (SHR). In a series of experiments, the compound the dopamine-beta-hydroxylase (DBH) catalyzed oxy-
when administered in doses ranging to 100 mg/kg, it genation of aminoalkyl phenyl selenides to the corre-
was demonstrated as very potent in lowering blood sponding selenoxides is the ability of the selenoxides to 
pressure of SHR and the aforesaid variation with dos- 40 oxidize the physiological electron donor, ascorbate, 
age levels was also demonstrated. When one group of with the concomittant and stoichiometric reduction of 
SHR was administered intraperitonally with the com- the selenoxides back to the selenide substrate. The oxy-
pound in a saline carrier at a dosage· of 50 mg/kg and a genation of aminoalkyl phenyl selenide by DBH, and 
control group was administered only with the saline the reduction of the enzymatic product, aminoalkyl 
carrier, a decrease in systemic blood pressure of approx- 45 phenyl selenoxide back to the selenide by ascorbate 
imately 30% in comparison with the control animals defines a cyclic path of ascorbate oxidation where an 
was observed. In addition, no adverse side effects from excess of ascorbate is oxidized per cycle, as illustrated in 
the chronic administration of the compound were ob- the Figure of the drawing. Thus, when compounds of 
served when given in daily dosages over a two week this invention are infused, it is likely that an enzymatic 
period, while substantial blood pressure reduction was 50 oxygenation/reduction cycle is initiated and sustained 
maintained. See Example 2 below. by the target enzyme dopamine-beta-hydroxylase. 
In treating hypertension in mammals by the method 
of this invention, it may not be necessary to administer EXAMPLE 1 
the aminoalkyl phenyl selenide in combination with a The ability of phenyl-2 aminoethyl selenoxide 
monoamine oxidase inhibitor, which would have the 55 (PAESeO) to oxidize ascorbate was explored. High 
effect of prolonging life of the active compounds in the pressure liquid chromatography (HPLC) was used to 
body. It has been found that when the (CHx)n substitu- show that the authentic selenoxide was stable at room 
ent of the compounds of the present invention is a temperature in the standard dopamine-beta-hydroxylase 
branched alkyl chain often carbons or less, the resulting (DBH) reaction mixture which did not contain ascor-
aminoalkyl phenyl selenide is a relatively inactive pro- 60 bate. Upon the addition of ascorbate to a final concen-
drug precursor which is potentiated by its enzymatic tration of 10 mM, P AESeO disappeared from the 
conversion into a highly active enzyme product. Thus, HPLC chromatogram and a peak with the same reten-
a monoamine oxidase inhibitor may not be desirable in tion time as phenyl-2 aminoethyl selenide (PAESe) 
the administration of such "branched" aminoalkyl appeared. As can be seen in Table I when a mixture of 
phenyl selenides. 65 IO mM P AESeO and 5 mM ascorbate in water was 
On the other hand, it has been found that compounds allowed to react for 24 minutes at room temperature, 
having a straight chain or "nonbranched" (CHx)n sub- HPLC analysis demonstrated that the concentration of 
stituent are relatively active, and may be potentiated by P AESeO was diminished by 50% at the expense of 
7 
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ascorbate and that a corresponding amount of P AESe 
was formed. Similarly, the reaction of 10 mM PAESeO 
and 10 mM ascorbate for 60 minutes resulted in the 
complete depletion of the selenoxide and the appear-
ance of a P AESe peak, the height of which correspond 5 
to 9.2 mM PAESe. These results demonstrate that 
P AESeO is stoichiometrically reduced to P AESe by 
ascorbate. In contrast to the reduction of P AESeO by 
ascorbate, the reaction of 10 mM PAESeO and 10 mM 
potassium ferrocyanide for 64 minutes did not result in 10 
the appearance of any P AESe or the loss of any 
PAESeO. 
TABLE I 
the animal's blood pressure to the normal hypertensive 
levels, suggesting the PAESe is catabolized and elimi-
nated by one of the normal physiological drug elimina-
tion pathways. 
Having now fully described the invention, it will be 
apparent to one of ordinary skill in the art that many 
changes and modifications can be made thereto without 
departing from the spirit or scope of the invention as set 
forth herein. 
What is claimed is: 
1. A method for depleting intracellular ascorbic acid 
in mammals comprising administering to the mammal 
an amount of an aminoalkyl phenyl selenide effective to 
initiate an oxidation/reduction cycle which is sustained STOICHIOMETRIC REDUCTION OF SELENOXIDE 
TO SELENIDE BY ASCORBATE 
Final Reaction Products 
Determined By High Pressure 
Liquid Chromatography 
15 by the target enzyme dopamine-beta-hydroxylase hav-
ing the formula: 
EXP Initial Composition of 
# Reaction Mixture 
2 
IOmM PAESeO 
10 mM Reduced Ascorbate 
!OmMPAESeO 
5 mM Reduced Ascrobate 
15 mM PAESeO 
5 mM Reduced Ascorbate 
PAESeO (mM) PAESe (mM) 
0 9.2 
5.2 
9.9 
5.1 
4.7 
20 
25 
wherein: 
EXAMPLE2 
The antihypertensive activity of l-phenyl-2-amino-
ethyl selenide (P AESe) was demonstrated in the follow-
ing experiment. Ten male spontaneously hypertensive 30 
rats (SHR), at 13 weeks of age, were obtained from 
Charles River Breeding Laboratories, Inc. SHR of the 
Okamoto-Aoki strain are an inbred rat strain derived 
from a mutant progenitor in which the defect which 
produces hypertension has been shown to be essential, 35 i.e., not renal hypertension (see Bey, P., Jung, M. J., and 
Loch-Weser, J., (1980) Brit. J. Pharmacol. 10, 571-576; 
Judy, W. V., Watanabe, A. M., Henry, D. P., Besch, H. 
R., Murphy, W.R., and Hockei, G. M., (1976) Circ. Res. 
38, Suppl. I: 21-29; and references in these for more 40 detail). Thus, this model of essential hypertension is an 
ideal one in which to test drugs for antihypertensive 
activity for eventual use in the treatment of human 
essential hypertension. 
The animals were housed for several weeks in an 
approved caging facility, allowed food and water ad 45 
libitum, and acclimated in 5-10 trials to an indirect 
systolic blood pressure monitoring protocol (tail-cuff 
plethysmographic measurement, Narco BioSystem, 
Inc.). The animals were divided into two groups of five 
and received either 50 mg/kg PAESe or saline, (1 so 
ml/kg) by subcutaneous injection at 24 hour intervals 
for seven consecutive days. Systolic blood pressure 
monitoring was performed using the indirect tail cuff 
method at one hour and three hours post-injection on 
each of the seven days. This testing revealed a signifi- 55 
cant 30% reduction in the blood pressure of the PA-
ESe-treated group, apparent after the initial 24 hours 
post-injection, and maintained for seven days. 
In these experiments, the test animals were conscious 
at all times during the experimentation, betrayed no 60 
behavioral changes as a result of the drug treatment, 
and sustained no weight losses as a result of the treat-
ment. Additionally, we have found that P AESe is non-
toxic in this animal model up to the highest levels tested 
so far, and that its blood pressure-lowering effects are 65 
reversible. That is, in animals who have received 
P AESe over a 3-7 day period at 24 hour intervals, 
withdrawal of this compound is marked by a return of 
R1-Rs=H, OH, C1-C4-alkoxy, C1-C4-alkyl, F, Cl, 
Br, or I; 
R6, R1=H, C1-C4-alkyl; and 
(CHx)n=any straight or branched, saturated or unsat-
urated alkyl chain of 10 carbons or less, n = 1 to 10 
carbons and x=O, 1, or 2 hydrogens; or a pharma-
ceutically acceptable salt thereof. 
2. The method as defined in claim 1 wherein the 
aminoalkyl phenyl selenide is phenyl-2-aminoethyl sele-
nide. 
3. The method as defined in claim 1 wherein said 
amount is 1-50 mg/kg of body weight of the mammal. 
4. A pharmaceutical composition comprising an ami-
noalkyl phenyl selenide compound having the formula: 
wherein: 
R1-R5=H, OH, C1-C4-alkoxy, C1-C4-alkyl, F, Cl, 
Br, or I; 
R6, R1=H, C1-C4-alkyl; and 
(CHx)n=any straight or branched, saturated or unsat-
urated alkyl chain of 10 carbons or less, n= 1 to 10 
carbons and x=O, l, or 2 hydrogens; and a pharma-
ceutically acceptable nontoxic excipient, said sele-
nide compound being present in an amount effec-
tive to deplete intracellular ascorbic acid in mam-
mals by initiating an oxidation/reduction cycle 
which is sustained by the target enzyme dopamine-
beta-hydroxylase. 
5. The method of claim 1 wherein the aminoalkyl 
phenyl selenide compound is administered in combina-
tion with a clinically utilized monamine oxidase inhibi-
tor, said inhibitor being selected from the group consist-
ing of clorgyline, deprenyl and nardil. 
* * * * * 
